Log in

CytomX Therapeutics Stock Forecast, Price & News

-0.06 (-0.91 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $6.56
50-Day Range
MA: $7.04
52-Week Range
Now: $6.56
Volume483,827 shs
Average Volume531,875 shs
Market Capitalization$302.79 million
P/E RatioN/A
Dividend YieldN/A
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Read More
CytomX Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CTMX



Sales & Book Value

Annual Sales$57.49 million
Book Value$1.12 per share


Net Income$-102,240,000.00


Market Cap$302.79 million
Next Earnings Date11/5/2020 (Estimated)
-0.06 (-0.91 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

How has CytomX Therapeutics' stock been impacted by Coronavirus (COVID-19)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 11.7% and is now trading at $6.5550.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CytomX Therapeutics

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for CytomX Therapeutics

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of $0.34 by $0.68. The biotechnology company earned $16.61 million during the quarter, compared to analyst estimates of $40.40 million. CytomX Therapeutics had a negative net margin of 73.51% and a negative return on equity of 95.68%.
View CytomX Therapeutics' earnings history

What price target have analysts set for CTMX?

8 analysts have issued twelve-month price targets for CytomX Therapeutics' stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate CytomX Therapeutics' stock price to reach $11.94 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.
View analysts' price targets for CytomX Therapeutics

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Pfizer (PFE), SCYNEXIS (SCYX), Alibaba Group (BABA) and Amicus Therapeutics (FOLD).

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (6.74%), Vanguard Group Inc. (5.74%), Perceptive Advisors LLC (5.58%), Victory Capital Management Inc. (4.96%), RTW Investments LP (3.28%) and Great Point Partners LLC (3.14%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends for CytomX Therapeutics

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Perceptive Advisors LLC, Victory Capital Management Inc., Spark Investment Management LLC, Prudential Financial Inc., Man Group plc, Vanguard Group Inc., and Tudor Investment Corp Et Al.
View insider buying and selling activity for CytomX Therapeutics

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Point72 Asset Management L.P., RTW Investments LP, Assenagon Asset Management S.A., Artal Group S.A., Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., and Grantham Mayo Van Otterloo & Co. LLC.
View insider buying and selling activity for CytomX Therapeutics

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $6.56.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $302.79 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.